N-cyclopentylcyclopentanecarboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-cyclopentylcyclopentanecarboxamide
• 化学式: C₁₁H₁₉NO
• mdl: MFCD01921297
• 分子量: 181.278
• InChiKey: SQIDXPKMRVYOHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  一氧化碳 、 环戊烯 在 bis(η3-allyl-μ-chloropalladium(II)) 、 盐酸羟胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 140.0 ℃ 、2.03 MPa 条件下， 反应 24.0h， 以74%的产率得到N-cyclopentylcyclopentanecarboxamide
  参考文献：
  名称：

  一种脂肪酰胺的制备方法

  摘要：

  本发明涉及一种脂肪酰胺的制备方法，该方法是指将盐酸羟胺、过渡金属、膦配体、烯烃和溶剂依次加入到高压反应釜中，在压力为5~30 atm的一氧化碳气氛中于50~150℃发生氢胺羰基化反应，1~48h后反应结束，经抽干溶剂、柱层析分离即得脂肪酰胺类化合物。本发明工艺简单、合成成本低、产率高，底物适用性范围宽，易于工业化。

  公开号：

  CN109293522B

文献信息

• [EN] METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR LE TRAITEMENT D'UNE MALADIE GÉNÉTIQUE
  申请人：DESIGN THERAPEUTICS INC

  公开号：WO2021158707A1

  公开（公告）日：2021-08-12

  The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

  本公开涉及化合物和方法，用于调节dmpk的表达，并治疗dmpk发挥积极作用的疾病和病况。该化合物可以是一种转录调节分子，具有第一末端、第二末端和寡聚骨架，其中：a）第一末端包括一种DNA结合基团，能够非共价结合到核苷酸重复序列CAG或CTG；b）第二末端包括结合到调节分子的蛋白结合基团，该调节分子调节包含核苷酸重复序列CAG或CTG的基因的表达；c）寡聚骨架包括连接第一末端和第二末端的连接物。
• [EN] QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLÉINE COMME INHIBITEURS DE BROMODOMAINE
  申请人：GILEAD SCIENCES INC

  公开号：WO2015080707A1

  公开（公告）日：2015-06-04

  This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula I, wherein R, R2, R3, R4, R7, W, X are as described herein and Z is selected from the group consisting of unsubstituted or substituted isoxazolyl, and unsubstituted or substituted pyrazolyl. Provided herein are also methods for the preparation and use of the compounds, and to pharmaceutical compositions containing the same.

  该申请涉及可能作为溴结构域含蛋白质的抑制剂或以其他方式调节溴结构域含蛋白质活性的化合物，包括溴结构域含蛋白质4（BRD4），以及含有这些化合物的组合物和配方，以及使用和制备这些化合物的方法。化合物包括式I的化合物，其中R、R2、R3、R4、R7、W、X如本文所述，Z选自未取代或取代的异唑啉基和未取代或取代的吡唑基。此外，还提供了制备和使用这些化合物的方法，以及含有这些化合物的药物组合物。
• Compound Combinations for Attenuation of Bacterial Virulence
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：US20170231962A1

  公开（公告）日：2017-08-17

  Methods for modulating quorum sensing in certain Gram-negative bacteria having multiple QS systems including Las, Rhl, and Pqs with associated receptors (LasR, RhlR and PqsR) which are modulated by small molecule modulators, particularly non-native modulators. Certain combinations of modulators of Las, Rhl and Pqs exhibit improved inhibition of virulence in comparison to the respective individual modulators. In particular, certain combinations of modulators exhibit improved inhibition in nutritionally depleted environments. More specifically, certain combinations of modulators exhibit improved inhibition in environments depleted in phosphate and/or environments depleted in iron. Nutrient depleted environments can mimic environments associated with bacterial infection in humans and non-human animals. The methods are useful in particular for modulating QS in Pseudomonas and Buckholderia.

  在某些具有多个QS系统的革兰氏阴性细菌中，包括具有相关受体（LasR、RhlR和PqsR）的Las、Rhl和Pqs的调控方法，这些受体受小分子调节剂（尤其是非天然调节剂）的调节。Las、Rhl和Pqs的某些调节剂组合相比于各自的单个调节剂表现出对毒力的改善抑制。特别是，某些调节剂组合在营养匮乏环境中表现出改善的抑制作用。更具体地说，某些调节剂组合在缺乏磷酸盐和/或缺乏铁的环境中表现出改善的抑制作用。营养匮乏环境可以模拟与人类和非人类动物细菌感染相关的环境。这些方法特别适用于调节假单胞菌和布氏杆菌中的QS。
• Synthetic ligands that modulate the activity of the RhlR quorum sensing receptor
  申请人：Wisconsin Alumni Research Foundation

  公开号：US11247976B2

  公开（公告）日：2022-02-15

  RhlR modulators including agonist and antagonists which are useful for modulating QS phenotypes in Gram-negative bacteria. Certain compounds of general formula A-W-HG having various carbocyclic ad heterocyclic head groups (HG) and various tail groups (A), where —W— is —CO—NH—, —SO2—NH—, —CO—NH—CH2—, or —SO2—NH—CH2— are RhlR agonists or antagonists. The compounds are useful in methods of modulating quorum sensing in Gram-negative bacteria, particularly in Pseudomonas. Compositions including certain RhlR modulators are useful for decreasing the virulence of Gram-negative bacteria. Pharmaceutical compositions comprising certain RhlR modulators are useful for treatment of infections of Gram-negative bacteria.

  RhlR 调节剂，包括激动剂和拮抗剂，可用于调节革兰氏阴性细菌的 QS 表型。通式 A-W-HG 的某些化合物具有各种碳环或杂环头基 (HG) 和各种尾基 (A)，其中 -W- 是 -CO-NH-、-SO2-NH-、-CO-NH-CH2- 或 -SO2-NH- - 是 RhlR 激动剂或拮抗剂。这些化合物可用于调节革兰氏阴性细菌，特别是假单胞菌的法定量感应。包括某些 RhlR 调节剂的组合物有助于降低革兰氏阴性细菌的毒力。包含某些 RhlR 调节剂的药物组合物可用于治疗革兰氏阴性细菌感染。
• Synthetic Ligands that Modulate the Activity of the RhlR Quorum Sensing Receptor
  申请人：Wisconsin Alumni Research Foundation

  公开号：US20190144407A1

  公开（公告）日：2019-05-16

  RhlR modulators including agonist and antagonists which are useful for modulating QS phenotypes in Gram-negative bacteria. Certain compounds of general formula A-W-HG having various carbocyclic ad heterocyclic head groups (HG) and various tail groups (A), where —W— is —CO—NH—, —SO 2 —NH—, —CO—NH—CH 2 —, or —SO 2 —NH—CH 2 — are RhlR agonists or antagonists. The compounds are useful in methods of modulating quorum sensing in Gram-negative bacteria, particularly in Pseudomonas . Compositions including certain RhlR modulators are useful for decreasing the virulence of Gram-negative bacteria. Pharmaceutical compositions comprising certain RhlR modulators are useful for treatment of infections of Gram-negative bacteria.